Skip to content

Randomized, Controlled Pilot-Study to Evaluate the Safety and immune regulatory effect of ProLon®, a Fasting-Mimicking Diet (FMD), on Inflammatory Cardiomyopathy (CMP)

Randomized, Controlled Pilot-Study to Evaluate the Safety and immune regulatory effect of ProLon®, a Fasting-Mimicking Diet (FMD), on Inflammatory Cardiomyopathy (CMP) - FMDiCMP

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
DRKS
Registry ID
DRKS00019897
Enrollment
40
Registered
2020-03-17
Start date
2019-08-05
Completion date
Unknown
Last updated
2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Inflammatory Cardiomyopathy I51.4

Interventions

Group 1: Intervention group (3 cycles of the ProLon™ fast-mimicking diet) Group 2: Control group (regular diet) Group 3: Control group after cross-over (3 cycles of the ProLon™ fast-mimicking diet a

Sponsors

Medizinische Klinik für Kardiologie am Campus Benjamin Franklin der Charité - Universitätsmedizin Berlin
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. Ability and willingness to provide written informed consent; 2. Ability and willingness to do the study tests; 3. Diagnosed with inflammatory cardiomyopathy based on myocardial biopsy

Exclusion criteria

Exclusion criteria: 1. Systolic blood pressure 10 mg daily) (based on medical history provided at screening); 12. Cancer diagnosis; 13. Unintentional weight loss >5% in the preceding 6 months 14. Uncontrolled severe hypertension (SBP/DBP >180/100) 15. Females who are pregnant or nursing

Design outcomes

Primary

MeasureTime frame
Shifts in the composition of inflammatory parameters (i.e. Th1-cytokines, Th17-cytokines, regulatory t-cells & naive t-cells) in the peripheral blood after 3 months of diet (regular vs. fast-mimicking diet), detected by means of FACS-analysis.

Secondary

MeasureTime frame
After 3 months of diet: Improvement of left ventricular ejection fraction; Decrease in ectopic beats and arrhythmias on 24 h Holter monitoring; Improved performance on exercise stress testing; Improvement of cardiac markers: High sensitivity Troponin T, myoglobin, NT-proBNP; Change in lifestyle and quality of life evaluated through Kansas City Cardiomyopathy Questionnaire (KCCQ)

Countries

Germany

Contacts

Public ContactBettina Heidecker

Klinik für Kardiologie, Charité, Campus Benjamin Franklin

bettina.heidecker@charite.de+49 30 450 513 783

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026